New shot could help kids with kidney disease avoid steroids

NCT ID NCT07087314

Recruiting now Disease control Sponsor: Mao Jianhua Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called SG301 in 30 children aged 6-18 who have nephrotic syndrome that keeps coming back or requires long-term steroids. The drug is given as a shot under the skin and aims to reduce relapses. Researchers will check safety and how well it works over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SG301 (anti-CD38 monoclonal antibody)
What this could lead to: If successful, this could offer a new treatment option to reduce relapses and steroid dependence in children with nephrotic syndrome.
What could go wrong: This is an early Phase 2 study with only 30 children, so results may not apply broadly. Side effects from the antibody are possible, and it may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEPHROTIC SYNDROME IN CHILDREN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nephrotic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEPHROTIC SYNDROME IN CHILDREN

Contacts and locations

Locations

Children's Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.